Keros Therapeutics Inc’s recently made public that its Chief Financial Officer Regnante Keith unloaded Company’s shares for reported $1.81 million on Nov 04 ’23. In the deal valued at $45.29 per share,40,000 shares were sold. As a result of this transaction, Regnante Keith now holds 0 shares worth roughly $0.0.
Then, Regnante Keith sold 20,000 shares, generating $908,367 in total proceeds. Upon selling the shares at $45.42, the Chief Financial Officer now owns 0 shares.
Before that, Regnante Keith sold 20,000 shares. Keros Therapeutics Inc shares valued at $955,872 were divested by the Chief Financial Officer at a price of $47.79 per share. As a result of the transaction, Regnante Keith now holds 0 shares, worth roughly $0.0.
William Blair initiated its Keros Therapeutics Inc [KROS] rating to an Outperform in a research note published recently. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in early December with a ‘”an Overweight”‘ rating. Wedbush began covering KROS with “an Outperform” recommendation on July 31, 2023. BofA Securities started covering the stock on July 26, 2023. It rated KROS as “a Buy”.
Price Performance Review of KROS
On Tuesday, Keros Therapeutics Inc [NASDAQ:KROS] saw its stock fall -1.06% to $55.19. Over the last five days, the stock has lost -4.84%. Keros Therapeutics Inc shares have risen nearly 38.81% since the year began. Nevertheless, the stocks have risen 21.94% over the past one year. While a 52-week high of $73.00 was reached on 02/29/24, a 52-week low of $27.02 was recorded on 01/02/24. SMA at 50 days reached $63.52, while 200 days put it at $44.09. A total of 0.48 million shares were traded, compared to the trading of 0.28 million shares in the previous session.
Levels Of Support And Resistance For KROS Stock
The 24-hour chart illustrates a support level at 53.85, which if violated will result in even more drops to 52.51. On the upside, there is a resistance level at 57.61. A further resistance level may holdings at 60.03. The Relative Strength Index (RSI) on the 14-day chart is 33.64, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.29, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.56%. Stochastics %K at 9.07% indicates the stock is a buying.
The most recent change occurred on February 14, 2023 when Cowen began covering the stock and recommended ‘”an Outperform”‘ rating .
